Login / Signup

Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.

Marlyn J MayoJohn M VierlingChristopher L BowlusCynthia LevyGideon M HirschfieldGuy W NeffMichael R GalambosStuart C GordonBrian B BorgStephen A HarrisonPaul J ThuluvathAparna GoelMitchell L ShiffmanMark G SwainDavid E J JonesPalak J TrivediAndreas E KremerRichard J AspinallDavid A SheridanYvonne DörffelKe YangYun-Jung ChoiCharles A McWherter
Published in: Alimentary pharmacology & therapeutics (2023)
gov: NCT03301506; Clinicaltrialsregister.eu: 2017-003910-16.
Keyphrases
  • open label
  • clinical trial
  • phase ii
  • phase iii
  • phase ii study
  • study protocol
  • ulcerative colitis
  • double blind